Edwards Lifesciences Corporation

EW · Healthcare · Health Care

Market cap

$52.2B

Price

$90.50

Daily change

-0.07%

Rank

#225

Updated 24 min ago · data delayed ≥15 min

IconicScore

Proprietary

51/ 100

Scale33

Momentum58

Sector leadership53

Brand visibility85

Ranked #215 of 500 by Iconic Score · #29 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.

Score trend · 88d+6 pts

Free · every trading day, 7 AM ET

Get the free morning email

The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →

Price performance

Export history · Analyst

Price$90.50+10.0%

$95$77

Apr 26Oct 26

IconicScore vs. price

This insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.

Upgrade to Analyst

Sector benchmark

This is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.

Upgrade to Enterprise

Iconic Profile

Edwards Lifesciences Corp (EW) is a leading global medical technology company specializing in heart valve solutions and hemodynamic monitoring. With a market capitalization of $48.4 billion, it focuses on innovative products for patients with structural heart disease and critical care monitoring. The company is recognized for its pioneering transcatheter aortic valve replacement (TAVR) technology, which has transformed treatment options for patients with aortic stenosis. Edwards Lifesciences holds a strong market position, driven by its commitment to research and development, extensive clinical evidence, and a robust pipeline of products. Its advancements not only improve patient outcomes but also address the growing demand for less invasive surgical options, making it a significant player in the evolving healthcare landscape.

IconicOracleAI™ Brief

Edwards Lifesciences Corp currently holds an Iconic Score of 49, reflecting a mixed brand perception influenced by recent developments. While the FDA approval of the PASCAL Precision System has generated positive attention, the company faces significant scrutiny due to a high-risk device recall linked to patient deaths. This duality in news coverage contributes to a volatile sentiment, despite a strong brand visibility signal of 85/100 from logo analysis.

AI-generated explanation of current score drivers. Not investment advice.

Visit website ↗Compare ⇄Claim this profile

Enterprise tier: claim your logo to manage how your brand is represented.